Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

To Explore the Treatment Effect of Various Commercially Available Statins on Patients With Hyperlipidemia

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00726362
First received: July 29, 2008
Last updated: December 2, 2010
Last verified: December 2010

July 29, 2008
December 2, 2010
December 2007
November 2009   (final data collection date for primary outcome measure)
Changes on LDL-C, HDL-C, TG, TC [ Time Frame: 3~6 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00726362 on ClinicalTrials.gov Archive Site
  • ratio for treatment-to-goal [ Time Frame: 3~6 months ] [ Designated as safety issue: No ]
  • drug compliance [ Time Frame: 3~6 months ] [ Designated as safety issue: No ]
  • correlation between patient's insight and therapeutic outcome [ Time Frame: 3~6 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
To Explore the Treatment Effect of Various Commercially Available Statins on Patients With Hyperlipidemia
To Explore the Treatment Effect of Various Commercially Available Statins on Patients With Hyperlipidemia

The primary objective is to survey the efficacy of various commercially available statins (a class of lipid-lowering agents, for example, rosuvastatin, atorvastatin, simvastatin, lovastatin, pravastatin and fluvastatin) under local clinical practice in treating patients with hyperlipidemia. Surveillance data (Lipid Profile) will be collected during course of usual clinical practice or captured upon its availability.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

based on regular practice and judged by physicians, patients with hyperlipidemia who need to start prescribed with a statin; or to switch from current therapy to a statin, or require dosage adjustment for statin

Hyperlipidemias
Not Provided
1
patients with hyperlipidemia newly initiating a statin; or switched from current therapy to a statin, or require dosage adjustment for statin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
3270
November 2009
November 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • patients diagnosed with hyperlipidemia
  • Patients who are just starting a statin treatment, who need to switch from current therapy to a statin medication, or who are receiving dosage adjustment of statin as judged by the physicians
  • Patients who are willing to participate in this study and who sign an informed consent form

Exclusion Criteria:

  • Pregnancy or breast feeding
  • Patient are illiterate or unable to fill the questionnaire for any reason
  • Patients with contraindications to the use of certain statins as needed prescribed by physicians (as per commercially available statins package insert) including the use of rosuvastatin.
  • Any clinical condition which, in the opinion of the attending physician, would not allow safe administration of the study medications
Both
20 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Taiwan
 
NCT00726362
NIS-CTW-CRE-2007/1
No
William Huang/Medical Director, AstraZeneca Pharmaceuticals
AstraZeneca
Not Provided
Principal Investigator: Wen-Ter Lai, MD Kaohsiung Medical University
AstraZeneca
December 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP